Oxidative Stress in Cardiovascular-Metabolic Diseases

2024
ISBN: 978-3-031-62130-7
Verlag: Springer Nature Switzerland

Buch, Englisch, 298 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 635 g

Reihe: Oxidative Stress in Applied Basic Research and Clinical Practice

The book dissects the role of oxidative stress in the pathogenesis of the leading causes of global morbidity and mortality, i.e. cardiovascular and metabolic diseases. The chapters discuss topics related to the role reactive oxygen species (ROS) play in hypertension, atherosclerosis, diabetes, obesity and related pathologies. One chapter discusses the clinical efficacy and safety considerations of GLP-1 receptor agonists and SGLT-2 inhibitors in obesity management and the associated cardiovascular complications. Another chapter discusses the context-dependent roles of matrix metalloproteases, and how their activity can be modulated and utilized for the development of improved drugs for cardiometabolic diseases. Moreover, how ROS and aging interplay to precipitate cardiovasculo-metabolic disease is discussed and highlighted. Similarly, how sex and sepsis interplay in the context of cardiorenal disease is teased out in one of the chapters. Preventive measures that can abrogate ROS-induced cardiovasclo-metabolic disease are discussed and clarified in the hope of reducing such a debilitating battery of diseases. Another chapter is fully dedicated to the roles of ROS in atherosclerosis, while another chapter deals with mechanisms and effect of ROS on various phenotypes of adipose tissues in the context of cardiovasculo-metabolic disease. A chapter also discusses the link between traumatic brain injury (TBI) and cardiovascular impairments, and how ROS plays a significant role in TBI-induced cardiovascular disease. A section dedicated to antioxidants as potential therapy is also included. Given the complexity of the mechanisms implicated in ROS-modulated responses, it remains challenging to assert a conclusive argument and pre-determined regimen for incorporating antioxidants into conventional therapies. In all of the chapters, the molecular, cellular, genetic, and pharmacological mechanisms implicated are covered from an applied science perspective.

This is an ideal book for basic researchers in the biomedical field, graduate students in biological and biomedical fields, medical students, instructors in medical and graduate schools, and professionals working for pharmaceutical companies.

Zielgruppe

Research

Autoren/Hrsg.

Eid, Ali Hussein

El-Yazbi, Ahmed F.

Kobeissy, Firas

Fachgebiete

• Naturwissenschaften Biowissenschaften Biowissenschaften
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Physiologie
• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

Chapter 1 - Interplay between ROS and gender in the pathogenesis of cardiovascular disease.- chapter 2 -ROS, aging and cardiovascular disease.- Chapter 3 - Combat ROS, prevent CVD.- Chapter 4 -Traumatic-brain injury and CVD: ROS is the link?.- Chapter 5 - Adipose tissue inflammation and CVD: oxidative stress as a catalyst.- Chapter 6 - Oxidative stress in diabetes-compounded CVD.- Chapter 7 - ROS in hypertension: a critical update.- Chapter 8 - ROS in atherosclerosis: what we know.-Chapter 9 - ROS as a key mediator of cardiovasculometabolic disease.- Chapter 10 - Antioxidant Therapy in CVD: hope or hype?.- Chapter 11 - Antioxidants as adjuvant therapy: Evidence from

clinical trials.

Über Autor(innen)

Dr. Ali Hussein Eid, PhD, is an Associate Professor of Pharmacology at Qatar University. Dr. Eid obtained his Ph.D. in Biomedical Sciences from the Ohio State University where he conducted his doctoral (and later postdoctoral) research at the Davis Heart and Lung Research Institute. He had previously obtained his MSc from Bowling Green State University, USA and his BSc from the American University of Beirut. The main research focus in Dr. Eid's laboratory is the molecular and cellular pharmacology that culminates in drug discovery. Dr. Eid has leveraged his training and experience in cellular and molecular biology to pursue research questions related to alpha 2 adrenoceptors (a2-ARs) in the context of vascular disease. Specifically, the role of the neuronal (norepinephrine), humoral (epinephrine) and endocrine (estrogen and cortisol) factors that govern the function of vascular a2-ARs is of prime importance. Dr. Eid runs a drug discovery program that looks at drugs of natural or synthetic origins. Dr. Eid is heavily involved in teaching medical students as well as graduate and undergraduate level courses, and as garnered several teaching awards. He also serves on the editorial board of several top-tier journals.

Firas Kobeissy, PhD is a Professor of Neuroscience at the Department of Neurobiology, Neuroscience Institute Morehouse School of Medicine (MSM), Atlanta, Georgia, USA. Dr Kobeissy serves as the Associate Director for the Center for Neurotrauma, Multiomics & Biomarkers (CNMB). Dr. Kobeissy obtained his Ph.D. from the University of Florida in the field of Neuroscience with a focus on brain injury. He obtained his Master’s degree from the American University of Beirut, Beirut, Lebanon. His research spans different animal and injury models assessing biomarker investigation utilizing different Multi-Omics applications related to different disease models. In addition to his research, Dr Kobeissy is involved in teaching medical and graduate at the MSM. Dr. Kobeissy has authored more than 300 articles, reviews, and book chapters along with two patents. He is the editor of nine books. Dr. Kobeissy has served on several national and international grant review panels including the NSF, NIH, DoD, and the Department of Veteran Affairs. He served as the past president of the International Brain Research Organization- MENA chapter (2020-2023).

Ahmed F. El-Yazbi is a Professor of Pharmacology and Therapeutic at the Faculty of Pharmacy in Alamein International University and Alexandria University in Egypt. He is also the Founding Director of the Research and Innovation Hub in Alamein International University. His research focuses on the role of localized adipose tissue inflammation in triggering cardiovascular and renal complications in the early stages of metabolic disease. He directs several basic and translational research projects aiming at the identification and validation of novel drugs and drug targets to offer disease modifying therapies in these indications.